Nikej Shah, M.D.
Chief Executive Officer
Dr. Shah is Founder, CEO, interim Chief Medical Officer and Co-Inventor of Nirsum’s foundational intellectual property. He brings over 20 years of experience in various roles as a physician, scientist and investor. Before Nirsum, Dr. Shah was the Founder and Managing Partner of biopharma-focused investment firm Mountain Brook Capital Management, LLC. He was previously a Senior Healthcare Portfolio Manager at Sigma Capital Management (now Point 72), and at HBK Capital Management. He was also a Managing Director at healthcare public/ private equity investor Great Point Partners and Analyst at Ursus Capital.
Dr. Shah earned an M.D. at the New York University School of Medicine and B.S. at Cornell University. He was also a practicing emergency physician, having completed residency at the New York University/Bellevue Hospital Center, where he gained extensive experience with the acute treatment and referral of patients with opioid use disorder (OUD).
Michael Tusche, Ph.D.
Chief Scientific Officer
Dr. Michael Tusche is Co-Founder, CSO, and Co-Inventor of Nirsum’s foundational intellectual property. He brings over 10 years of experience in various roles within the biotech sector. Before Nirsum, Michael was a Senior Biotechnology Analyst at Mountain Brook Capital Management, LLC, and a Biotechnology Associate Analyst at MLV and Co. Prior to that, Dr. Tusche led Biologic drug discovery at the Campbell Family Institute in Toronto, Canada, where he managed a multidisciplinary R&D team in the pre-clinical development of novel drug candidates. He was also a Scientist in drug discovery at Bayer AG, where he worked on early stage validation of small molecule GPCR antagonists.
Dr. Tusche received his B.Sc. from the University of Victoria. He also received a Ph.D. in Immunology and M.B.A.from the University of Toronto. He is co-author on several peer-reviewed publications, the recipient of numerous scientific awards, and named inventor on 5 issued US biopharmaceutical patents.